Lexicon Pharmaceutcl (LXRX) 18.63 $LXRX Interes
Post# of 273254
Posted On: 09/25/2016 9:05:32 AM
Lexicon Pharmaceutcl (LXRX) 18.63 $LXRX
Interesting LXRX Put And Call Options For November 18th
DividendChannel.com - Tue Sep 20, 10:01AM CDT
Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the November 18th expiration.
LXRX: 18.63 (-0.19)
Lexicon Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 1.91%
Comtex SmarTrend(R) - Thu Sep 15, 3:17PM CDT
Lexicon Pharmaceuticals (NASDAQ:LXRX) traded in a range yesterday that spanned from a low of $18.46 to a high of $19.35. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $19.15 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LXRX: 18.63 (-0.19)
FDA Extends PDUFA Date For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
PR Newswire - Wed Sep 14, 4:46PM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration ("FDA"
will require additional time to complete its review of the New Drug Application ("NDA" for telotristat etiprate, an oral drug for the treatment of carcinoid syndrome. In a notice received from the FDA, the Prescription Drug User Fee Act ("PDUFA" date for its Priority Review of telotristat etiprate has been extended by three months, from November 30, 2016 to February 28, 2017. In response to an information request from the FDA, additional clinical data analyses have been submitted and the extension will provide the FDA time for a full review of the submission.
LXRX: 18.63 (-0.19)
Biotech Stock Roundup: Horizon-Raptor Acquisition Deal, Geron Down on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Sep 14, 7:47AM CDT
With the Horizon-Raptor acquisition deal being announced, will the biotech sector see more such merger and acquisition announcements?
BIIB: 312.58 (-2.23), RPTP: 9.00 (+0.03), LXRX: 18.63 (-0.19), GILD: 81.37 (-0.15), GERN: 2.20 (-0.02), HZNP: 19.43 (+0.02), SPPI: 4.72 (-0.09)
Lexicon Hits 52-Week High on Positive Type I Diabetes Data
Zacks Equity Research - Zacks Investment Research - Mon Sep 12, 10:33AM CDT
Lexicon Pharmaceuticals (LXRX) hits 52-week high after sotagliflozin hit primary endpoint in a phase III study in patients with type I diabetes.
LXRX: 18.63 (-0.19), GERN: 2.20 (-0.02), ANIK: 46.92 (-1.07), SNY: 38.35 (-0.22)
Company News for September 12, 2016
Zacks Equity Research - Zacks Investment Research - Mon Sep 12, 9:10AM CDT
Companies in the News are: HOV,RH,LXRX,FNSR
FNSR: 29.22 (-0.11), RH: 32.88 (-0.36), LXRX: 18.63 (-0.19), HOV: 1.72 (unch)
Lexicon Pharmaceuticals (LXRX) Jumps: Stock Rises 16.6%
Zacks Equity Research - Zacks Investment Research - Mon Sep 12, 7:25AM CDT
Lexicon Pharmaceuticals, Inc. (LXRX) moved big last session, as its shares jumped almost 17% on the day.
LXRX: 18.63 (-0.19), GERN: 2.20 (-0.02)
Lexicon Pharmaceuticals Rises 17.96% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Sep 09, 1:45PM CDT
Lexicon Pharmaceuticals (NASDAQ:LXRX) traded in a range yesterday that spanned from a low of $17.70 to a high of $19.19. Yesterday, the shares gained 18.0%, which took the trading range above the 3-day high of $15.32 on volume of 9.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LXRX: 18.63 (-0.19)
Lexicon Reports Positive Top-Line Results In Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes
PR Newswire - Fri Sep 09, 5:58AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that the pivotal inTandem1 Phase 3 clinical trial of sotagliflozin met its primary endpoint, showing a statistically significant reduction in A1C at 24 weeks in patients with type 1 diabetes on a background of optimized insulin.
LXRX: 18.63 (-0.19)
Lexicon To Present At The Bank Of America Merrill Lynch Global Health Care Conference
PR Newswire - Wed Sep 07, 3:01PM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Bank of America Merrill Lynch Health Care Conference in London on Thursday, September 15, 2016 at 1:00 p.m. BST (8:00 a.m. EDT). Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 18.63 (-0.19)
Lexicon To Present At The 2016 Wedbush PacGrow Healthcare Conference
PR Newswire - Fri Aug 12, 7:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday, August 17, 2016 at 8:35 a.m. Eastern Time in New York. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 18.63 (-0.19)
Lexicon Pharmaceuticals Up 40.8% Since SmarTrend Uptrend Call (LXRX)
Comtex SmarTrend(R) - Thu Aug 11, 1:06PM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 5 months, Lexicon Pharmaceuticals has returned 40.77% as of today's recent price of $15.90.
LXRX: 18.63 (-0.19)
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Second Quarter Financial Results
PR Newswire - Thu Aug 04, 6:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the second quarter ended June 30, 2016 and provided an overview of key milestones for the company's lead drug candidates.
LXRX: 18.63 (-0.19)
Lexicon Pharmaceuticals Shares Up 42.7% Since SmarTrend's Buy Recommendation (LXRX)
Comtex SmarTrend(R) - Thu Aug 04, 12:31AM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 5 months, Lexicon Pharmaceuticals has returned 42.72% as of today's recent price of $16.12.
LXRX: 18.63 (-0.19)
Lexicon To Report Second Quarter 2016 Financial Results On August 4, 2016
PR Newswire - Mon Aug 01, 3:01PM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2016 financial results on Thursday, August 4, 2016 before the financial markets open. Lexicon management will hold a conference call and webcast to discuss clinical development progress and second quarter financial results at 10:00 a.m. Eastern Time on August 4, 2016.
LXRX: 18.63 (-0.19)
43.9% Return Seen to Date on SmarTrend Lexicon Pharmaceuticals Call (LXRX)
Comtex SmarTrend(R) - Wed Jul 27, 12:57PM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 5 months, Lexicon Pharmaceuticals has returned 43.87% as of today's recent price of $16.25.
LXRX: 18.63 (-0.19)
Lexicon Pharmaceuticals Shares Up 20.8% Since SmarTrend's Buy Recommendation (LXRX)
Comtex SmarTrend(R) - Thu Jun 16, 1:40PM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 4 months, Lexicon Pharmaceuticals has returned 20.76% as of today's recent price of $13.64.
LXRX: 18.63 (-0.19)
Shares of LXRX Up 30.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 09, 12:45AM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 3 months, Lexicon Pharmaceuticals has returned 30.41% as of today's recent price of $14.73.
LXRX: 18.63 (-0.19)
Lexicon To Present At The Jefferies 2016 Healthcare Conference
PR Newswire - Mon Jun 06, 3:01PM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 8:30 a.m. Eastern Time in New York. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 18.63 (-0.19)
Premarket Research Report Covering the Biotech Industry
ACCESSWIRE - Mon Jun 06, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 6, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the biotech industry. Companies recently under review include Incyte, Chimerix, Lexicon Pharma, and Synthetic Biologics. Register with us now for your free membership and see our complete reports on these equities at:
SYN: 1.75 (-0.02), CMRX: 5.72 (-0.03), LXRX: 18.63 (-0.19), INCY: 88.98 (-0.29)
Interesting LXRX Put And Call Options For November 18th
DividendChannel.com - Tue Sep 20, 10:01AM CDT
Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the November 18th expiration.
LXRX: 18.63 (-0.19)
Lexicon Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 1.91%
Comtex SmarTrend(R) - Thu Sep 15, 3:17PM CDT
Lexicon Pharmaceuticals (NASDAQ:LXRX) traded in a range yesterday that spanned from a low of $18.46 to a high of $19.35. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $19.15 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LXRX: 18.63 (-0.19)
FDA Extends PDUFA Date For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
PR Newswire - Wed Sep 14, 4:46PM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration ("FDA"
will require additional time to complete its review of the New Drug Application ("NDA" for telotristat etiprate, an oral drug for the treatment of carcinoid syndrome. In a notice received from the FDA, the Prescription Drug User Fee Act ("PDUFA" date for its Priority Review of telotristat etiprate has been extended by three months, from November 30, 2016 to February 28, 2017. In response to an information request from the FDA, additional clinical data analyses have been submitted and the extension will provide the FDA time for a full review of the submission. LXRX: 18.63 (-0.19)
Biotech Stock Roundup: Horizon-Raptor Acquisition Deal, Geron Down on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Sep 14, 7:47AM CDT
With the Horizon-Raptor acquisition deal being announced, will the biotech sector see more such merger and acquisition announcements?
BIIB: 312.58 (-2.23), RPTP: 9.00 (+0.03), LXRX: 18.63 (-0.19), GILD: 81.37 (-0.15), GERN: 2.20 (-0.02), HZNP: 19.43 (+0.02), SPPI: 4.72 (-0.09)
Lexicon Hits 52-Week High on Positive Type I Diabetes Data
Zacks Equity Research - Zacks Investment Research - Mon Sep 12, 10:33AM CDT
Lexicon Pharmaceuticals (LXRX) hits 52-week high after sotagliflozin hit primary endpoint in a phase III study in patients with type I diabetes.
LXRX: 18.63 (-0.19), GERN: 2.20 (-0.02), ANIK: 46.92 (-1.07), SNY: 38.35 (-0.22)
Company News for September 12, 2016
Zacks Equity Research - Zacks Investment Research - Mon Sep 12, 9:10AM CDT
Companies in the News are: HOV,RH,LXRX,FNSR
FNSR: 29.22 (-0.11), RH: 32.88 (-0.36), LXRX: 18.63 (-0.19), HOV: 1.72 (unch)
Lexicon Pharmaceuticals (LXRX) Jumps: Stock Rises 16.6%
Zacks Equity Research - Zacks Investment Research - Mon Sep 12, 7:25AM CDT
Lexicon Pharmaceuticals, Inc. (LXRX) moved big last session, as its shares jumped almost 17% on the day.
LXRX: 18.63 (-0.19), GERN: 2.20 (-0.02)
Lexicon Pharmaceuticals Rises 17.96% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Sep 09, 1:45PM CDT
Lexicon Pharmaceuticals (NASDAQ:LXRX) traded in a range yesterday that spanned from a low of $17.70 to a high of $19.19. Yesterday, the shares gained 18.0%, which took the trading range above the 3-day high of $15.32 on volume of 9.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LXRX: 18.63 (-0.19)
Lexicon Reports Positive Top-Line Results In Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes
PR Newswire - Fri Sep 09, 5:58AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that the pivotal inTandem1 Phase 3 clinical trial of sotagliflozin met its primary endpoint, showing a statistically significant reduction in A1C at 24 weeks in patients with type 1 diabetes on a background of optimized insulin.
LXRX: 18.63 (-0.19)
Lexicon To Present At The Bank Of America Merrill Lynch Global Health Care Conference
PR Newswire - Wed Sep 07, 3:01PM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Bank of America Merrill Lynch Health Care Conference in London on Thursday, September 15, 2016 at 1:00 p.m. BST (8:00 a.m. EDT). Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 18.63 (-0.19)
Lexicon To Present At The 2016 Wedbush PacGrow Healthcare Conference
PR Newswire - Fri Aug 12, 7:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday, August 17, 2016 at 8:35 a.m. Eastern Time in New York. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 18.63 (-0.19)
Lexicon Pharmaceuticals Up 40.8% Since SmarTrend Uptrend Call (LXRX)
Comtex SmarTrend(R) - Thu Aug 11, 1:06PM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 5 months, Lexicon Pharmaceuticals has returned 40.77% as of today's recent price of $15.90.
LXRX: 18.63 (-0.19)
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Second Quarter Financial Results
PR Newswire - Thu Aug 04, 6:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the second quarter ended June 30, 2016 and provided an overview of key milestones for the company's lead drug candidates.
LXRX: 18.63 (-0.19)
Lexicon Pharmaceuticals Shares Up 42.7% Since SmarTrend's Buy Recommendation (LXRX)
Comtex SmarTrend(R) - Thu Aug 04, 12:31AM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 5 months, Lexicon Pharmaceuticals has returned 42.72% as of today's recent price of $16.12.
LXRX: 18.63 (-0.19)
Lexicon To Report Second Quarter 2016 Financial Results On August 4, 2016
PR Newswire - Mon Aug 01, 3:01PM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2016 financial results on Thursday, August 4, 2016 before the financial markets open. Lexicon management will hold a conference call and webcast to discuss clinical development progress and second quarter financial results at 10:00 a.m. Eastern Time on August 4, 2016.
LXRX: 18.63 (-0.19)
43.9% Return Seen to Date on SmarTrend Lexicon Pharmaceuticals Call (LXRX)
Comtex SmarTrend(R) - Wed Jul 27, 12:57PM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 5 months, Lexicon Pharmaceuticals has returned 43.87% as of today's recent price of $16.25.
LXRX: 18.63 (-0.19)
Lexicon Pharmaceuticals Shares Up 20.8% Since SmarTrend's Buy Recommendation (LXRX)
Comtex SmarTrend(R) - Thu Jun 16, 1:40PM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 4 months, Lexicon Pharmaceuticals has returned 20.76% as of today's recent price of $13.64.
LXRX: 18.63 (-0.19)
Shares of LXRX Up 30.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 09, 12:45AM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 3 months, Lexicon Pharmaceuticals has returned 30.41% as of today's recent price of $14.73.
LXRX: 18.63 (-0.19)
Lexicon To Present At The Jefferies 2016 Healthcare Conference
PR Newswire - Mon Jun 06, 3:01PM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 8:30 a.m. Eastern Time in New York. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 18.63 (-0.19)
Premarket Research Report Covering the Biotech Industry
ACCESSWIRE - Mon Jun 06, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 6, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the biotech industry. Companies recently under review include Incyte, Chimerix, Lexicon Pharma, and Synthetic Biologics. Register with us now for your free membership and see our complete reports on these equities at:
SYN: 1.75 (-0.02), CMRX: 5.72 (-0.03), LXRX: 18.63 (-0.19), INCY: 88.98 (-0.29)
(0)
(0)Scroll down for more posts ▼